Clinical and Echocardiographic Outcomes After Implantation of the ALLEGRA Transcatheter Valve Using the Fully Repositionable IMPERIA Delivery System: One‐Year Results of the EMPIRE I Study
Catheterization and Cardiovascular Interventions · 2026-08 · 108 (2) · 540-547
DOI: 10.1002/ccd.70675 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Catheterization and Cardiovascular Interventions, online erschienen am 31.05.2026. Verfasst von José Antonio Baz und 15 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Cardiología, Hospital Alvaro Cunqueiro, Vigo, Spain. Hauptthemen laut MEDLINE: Heart Valve Prosthesis, Aortic Valve Stenosis, Bioprosthesis, Aortic Valve. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Biosensors Europe SA.
Abstract (Originalsprache)
Background
The EMPIRE I study assessed the early (30 days) safety and efficacy of a new fully repositionable delivery system (IMPERIA) for the commercially available ALLEGRA transcatheter aortic valve in patients with either severe native aortic stenosis or a degenerated surgical bioprosthesis.
Aim
To report the final 1‐year results of the EMPIRE I study.
Methods
EMPIRE I is a pre‐market, prospective, multi‐center, single‐arm study conducted at 11 centers in 3 European countries. There were independent data safety and clinical events committees and an independent echocardiographic core laboratory. In this analysis, VARC‐3 definitions of all clinical endpoints and echocardiographic parameters were employed.
Results
The study recruited 121 patients with severe native aortic stenosis and 16 with degenerated surgical bioprosthesis. At 1 year, the incidence of bioprosthetic valve dysfunction in the native population was 5.9%. No patients developed structural valve deterioration or endocarditis, and there were no patients with haemodynamic valve deterioration or bioprosthetic valve failure. In the valve‐in‐valve sub‐group, 2/14 (14.3%) patients had moderate patient prosthesis mismatch at 30 days with no evidence of new bioprosthetic valve dysfunction at 1 year. In the native population, new permanent pacemaker implantation was 14.3% at 30 days and remained unchanged at 1 year. Cardiovascular mortality was 6.8% in the native population and 0% in the valve‐in‐valve patients. At 1‐year, all‐cause mortality was 10.8% (95% CI 6.4%−17.8%) in the native aortic stenosis population and 0% in the valve‐in‐valve patients.
Conclusion
After 1 year of follow‐up, the results of the EMPIRE 1 study show excellent haemodynamic performance, a low rate of bioprosthetic valve dysfunction, and no bioprosthetic valve failure in patients treated with the ALLEGRATM trans‐catheter aortic valve implanted using the new IMPERIATM fully repositionable delivery system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Servicio de Cardiología, Hospital Alvaro Cunqueiro, Vigo, Spain.
- Department of Cardiology, Cardiovascular Institute, Erasmus Medical Center, Rotterdam, The Netherlands.
- Cardialysis, Rotterdam, The Netherlands.
- Herz- und Gefäßzentrum, Bad Bevensen, Germany.
- Department of Cardiology, Universitätsklinik Schleswig-Holstein Campus Lübeck, Lübeck, Germany.
- Servicio de Cardiología, Hospital Universitario de Salamanca, Salamanca, IBSAL, CIBER CV, Salamanca, Spain.
ORCID-Profile: Nicolas van Mieghem
Förderung
- Biosensors Europe SA
Zitieren
APA
Baz, J. A., Ren, C. B., Burgdorf, C., Frerker, C., Cruz-González, I., Gómez, J. A., Hernândez, J. M., Jimenez, P., Spitzer, E., Tonino, P., Vriesendorp, P., van Mieghem, N., Copt, S., Jönsson, A., Oldroyd, K. G., & Doll, N. (2026). Clinical and Echocardiographic Outcomes After Implantation of the ALLEGRA Transcatheter Valve Using the Fully Repositionable IMPERIA Delivery System: One‐Year Results of the EMPIRE I Study. Catheterization and Cardiovascular Interventions, 108(2), 540-547. https://doi.org/10.1002/ccd.70675
Vancouver
Baz JA, Ren CB, Burgdorf C, Frerker C, Cruz-González I, Gómez JA, et al. Clinical and Echocardiographic Outcomes After Implantation of the ALLEGRA Transcatheter Valve Using the Fully Repositionable IMPERIA Delivery System: One‐Year Results of the EMPIRE I Study. Catheterization and Cardiovascular Interventions. 2026;108(2):540-547. doi:10.1002/ccd.70675
BibTeX
@article{Baz2026,
author = {Baz, José Antonio and Ren, Claire B and Burgdorf, Christof and Frerker, Christian and Cruz-González, Ignacio and Gómez, Joan Antoni and Hernândez, José Maria and Jimenez, Pilar and Spitzer, Ernest and Tonino, Pim and Vriesendorp, Pieter and van Mieghem, Nicolas and Copt, Samuel and Jönsson, Anders and Oldroyd, Keith G and Doll, Nicolas},
title = {Clinical and Echocardiographic Outcomes After Implantation of the ALLEGRA Transcatheter Valve Using the Fully Repositionable IMPERIA Delivery System: One‐Year Results of the EMPIRE I Study},
journal = {Catheterization and Cardiovascular Interventions},
year = {2026},
volume = {108},
number = {2},
pages = {540--547},
doi = {10.1002/ccd.70675}
}
EUVIMED